You are here

PrEP — where are we at?

In May last year, the Therapeutic Goods Administration (TGA) gave Truvada its tick for use as a drug to protect against HIV. Describing the TGA’s decision as a “revolutionary development”, Darryl O’Donnell, Executive Director of the Australian Federation of AIDS Organisations (AFA0), said at the time: “In registering Truvada, the TGA has confirmed that this is a safe and effective way of preventing HIV transmission through sex. Truvada for PrEP gives people at risk a powerful new option for taking control of their health; it puts them in control to stay HIV-negative.”

PrEP also offers enormous benefits to HIV-positive people as well. “It is an important new method of practicing safer sex with partners,” said Aaron Cogle, Executive Director of the National Association of People with HIV Australia. “Using PrEP with Treatment as Prevention (TasP) allows both partners to share the responsibility for HIV prevention; it reduces the stress and anxiety that can be associated with HIV and sex. This means less pressure on positive people in casual sexual encounters and in serodiscordant relationships.” 

With TGA approval out of the way, the focus of attention quickly shifted to affordability. “For PrEP to have maximum impact, it is vital that anyone who is at high risk of becoming HIV-positive is able to afford it,” said NAPWHA president Cipri Martinez. “The only way for that to be achieved is for Truvada to be placed on the Pharmaceutical Benefits Scheme (PBS) as soon as possible.” O’Donnell agreed: “We have a national, bipartisan commitment to virtually eliminate HIV transmission in Australia by 2020. Affordable, PBS-listed PrEP would make all the difference.”

When the Pharmaceutical Benefits Advisory Board (PBAC) met in August 2016, it was widely expected that PrEP would receive the rubber stamp for subsidy.  However, the submission was rejected. PBAC cited cost as the main reason behind its decision, describing the price submitted by manufacturer Gilead Sciences as not “feasible to clinicians and consumers”. 

O’Donnell expressed “great disappointment” at the news. “Without PBS listing, [PrEP] is a wasted tool,” he said. “This is proven technology.” Calls were subsequently made for Gilead to reapply with a revised financial model. “One that’s more realistic, more sustainable, and puts people before profits,” said Martinez. In reply, PBAC said it would welcome another submission from Gilead, one that addressed “the concerns about cost effectiveness”.

Which brings us to now. Gilead intends to resubmit its application to PBAC within months, with an outcome expected in July. What that outcome will be is still anyone’s guess. One thing is certain though, as O’Donnell said: “People are needlessly getting HIV while we wait for access to this prevention pill.”


latest news

May 9, 2018 , Posted by Christopher
The federal government's budget details were released last night. Here's a community response.
March 29, 2018 , Posted by Christopher
We’re not talking about recovery parties here, but the post-recovery recovery when the festivities have ended.
March 21, 2018 , Posted by Christopher
The world has lost one of the most respected scientists in the field of HIV/AIDS, Professor David Cooper.
March 21, 2018 , Posted by Christopher
The cost of PrEP (pre-exposure prophylaxis) is to be drastically reduced from 1 April
February 12, 2018 , Posted by Christopher
The annual awareness day on 9 March is aimed at encouraging women to test for HIV.
January 22, 2018 , Posted by Christopher
Once again, 9 March commemorates the National Day of Women Living with HIV Australia. 
November 30, 2017 , Posted by Christopher
On a trip to Bali, David Menadue discovered that it pays to be clued up about travel insurance.
November 30, 2017 , Posted by Christopher
Armistead Maupin talks to Steven Petrow about 1970s San Francisco, AIDS and ageing.
November 30, 2017 , Posted by Christopher
This year marks the 30th anniversary of the AIDS Memorial Quilt. Read the story behind the icon.
November 29, 2017 , Posted by Christopher
They are the all-too forgotten minority: heterosexual men with HIV. Here are their stories.
November 29, 2017 , Posted by Christopher
In 2018, researchers will explore a number of approaches that might bring an end to the need for treatment.
November 29, 2017 , Posted by Christopher
As people with HIV get older and live longer, they become vulnerable to cardiovascular disease. 
August 22, 2017 , Posted by Christopher
A decision to subsidise PrEP has been deferred, much to the disappointment and frustration of HIV advocates.
July 26, 2017 , Posted by Christopher
Results from an Australian study show that HIV-positive men on treatment cannot transmit the virus.
June 22, 2017 , Posted by Christopher
Why is an easily curable disease once believed to be on the wane in Australia out of control?